Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CHKB-CPT1B | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | LAT2 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
mRNA | LUC7L | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | LATS1 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | SYS1 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
mRNA | CHD3 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | RP11-15H20.8 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | KCNA6 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | NONO | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | ZMYM2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |